{"id":3653,"date":"2025-03-31T18:11:46","date_gmt":"2025-03-31T18:11:46","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/abciximab-txt\/"},"modified":"2025-03-31T18:11:46","modified_gmt":"2025-03-31T18:11:46","slug":"abciximab-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/abciximab-txt\/","title":{"rendered":"Abciximab.txt"},"content":{"rendered":"

Abciximab<\/h1>\n

CLINICAL USE <\/H3>Antiplatelet agent:<\/p>\n
  • Prevention of ischaemic cardiac\n
  • complications in patients undergoing percutaneous coronary intervention\n
  • Short-term prevention of myocardial infarction in patients with unstable angina not responding to treatment or awaiting percutaneous coronary intervention

    DOSE IN NORMAL RENAL FUNCTION <\/H3>IV bolus: 250 mcg\/kg then by infusion at 0.125 mcg\/kg\/minute for 12 hours after intervention (maximum 10 mcg\/minute)

    PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :47 455.4<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Binds to platelets<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : Minimal (catabolised like other proteins)<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :0.1181<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :<10 minutes\/unchanged

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function. Use with caution

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in GFR <10 mL\/min<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Unlikely to be dialysed. Dose as in GFR <10 mL\/min
  • HDF\/high flux &nbsp :Unlikely to be dialysed. Dose as in GFR <10 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugsHeparin, anticoagulants, antiplatelets and thrombolytics: increased risk of bleeding

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>IV bolus,

    IV infusion <\/H4>

    Rate of Administration <\/H4>Bolus: 1 minute Infusion: 0.125 mcg\/kg\/minute (maximum 10 mcg\/minute)

    Comments<\/H4>Dilute in sodium chloride 0.9% or glucose 5%Give via a non-pyrogenic low-protein- binding 0.2, 0.22 or 5 micron filter

    OTHER INFORMATION <\/H4>\n
  • Increased risk of bleeding in CKD 5, benefits of abciximab treatment may be reduced\n
  • In the UK the licence says avoid in haemodialysis patients due to increased risk of bleeding (as on heparin for dialysis) but it is used in normal doses in the USA\n
  • Antibodies to abciximab develop 2\u20134 weeks post dose in 5.8% of patients so monitor for hypersensitivity reactions if re-administered\n
  • Abciximab remains in the body for at least 15 days, bound to platelets\n
  • Once infusion is stopped, the concentration of abciximab falls rapidly for 6 hours then decreases at a slower rate
    \n","protected":false},"excerpt":{"rendered":"

    Abciximab CLINICAL USE Antiplatelet agent: Prevention of ischaemic cardiac complications<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3653","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3653","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3653"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3653\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3653"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3653"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3653"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}